12:00 AM
 | 
Nov 16, 2009
 |  BC Week In Review  |  Company News  |  Deals

Enzon, Sigma-Tau S.p.A. deal

Sigma-Tau, which said the deal will increase its presence in the field of rare diseases, also will acquire Enzon's Indianapolis, Ind. manufacturing facility. Goldman Sachs and Greenhill advised Enzon. The deal is expected to close in 1Q10. Enzon began seeking strategic alternatives for its specialty pharmaceuticals business last year (see BioCentury, Aug. 18, 2008).

Enzon retains its royalties,...

Read the full 273 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >